Aladdin Healthcare Technologies Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Wade Menpes-Smith
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2021 | n/a | n/a | €12k |
| Mar 31 2021 | n/a | n/a | -€610k |
| Dec 31 2020 | n/a | n/a | -€1m |
| Sep 30 2020 | n/a | n/a | -€2m |
| Jun 30 2020 | n/a | n/a | -€3m |
| Mar 31 2020 | n/a | n/a | -€3m |
| Dec 31 2019 | €137k | €100k | -€3m |
| Sep 30 2019 | n/a | n/a | -€4m |
| Jun 30 2019 | n/a | n/a | -€4m |
| Mar 31 2019 | n/a | n/a | -€4m |
| Dec 31 2018 | €205k | €170k | -€5m |
Compensation vs Market: Insufficient data to establish whether Wade's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Insufficient data to compare Wade's compensation with company performance.
CEO
Wade Menpes-Smith
no data
Tenure
Mr. Wade Menpes-Smith serves as Chief Executive Officer, Managing Director & Chairman of the Board of Directors at Aladdin Healthcare Technologies SE (formerly known as Aladdin Blockchain Technologies Hold...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | no data | no data | no data | |
| Deputy Chairman & COO | no data | no data | no data | |
| CFO & Director | 3.5yrs | no data | no data | |
| Member of Drug Discovery Advisory Board & Chief Scientific Advisor | 3.7yrs | no data | no data | |
| Member of Early Diagnosis Advisory Board & Adviser of Early Stage Drug Discovery | 5.3yrs | no data | no data | |
| Member of Drug Advisory Board & Adviser of Neurological Research | 5.3yrs | no data | no data | |
| Member of Early Diagnosis Advisory Board & Adviser of Aging | 5.3yrs | no data | no data | |
| Member of Early Diagnosis Advisory Board & Adviser of Biological Research | 5.3yrs | no data | no data | |
| Member of Drug Advisory Board & Adviser of Cardiovascular | 5.3yrs | no data | no data | |
| Member of Drug Discovery Advisory Board & Adviser of Medical Imaging | 5.3yrs | no data | no data | |
| Member of Drug Discovery Advisory Board & Adviser of Biobank | 4.4yrs | no data | no data |
5.3yrs
Average Tenure
Experienced Board: NMI's board of directors are considered experienced (5.3 years average tenure).